SSgA Funds Management, Inc. has recently announced that it has increased stake in Pfizer Inc. (NYSE:PFE) by 2.15%. After grabbing 298.9 million shares, the institutional investor is now in possession of 6.28 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 5.38% having worth around $11.5 billion. Moreover, BlackRock Fund Advisors increased its share by 9.49 million to have a control over 279.95 million shares. And Wellington Management Co. LLP raised its holdings to 32.18 million shares by acquiring 250.85 million shares or 4.52% of the stake.
Pfizer Inc. (PFE) concluded trading on 08/27/20 at a closing price of $37.86, with 20.65 million shares of worth about $781.67 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -2.22% during that period and on Thursday the price saw a loss of about -0.50%. Currently the company’s common shares owned by public are about 5.55B shares, out of which, 5.55B shares are available for trading.
Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $53.00 and could fall to a lowest price of $35.00. Analysts also issued an outlook of 2.50 for the Pfizer Inc. stock for next 12 months. The stock’s current price level is 9.53% above of average price target set by the analysts, while a rise to estimated low would result in loss of -8.17 for the stock. However, touching the estimated high of $53.00 would mean a gain of 28.57% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 114 times over the past 12 months. They bought 1,479,692 shares in 38 of the transactions. In 76 selling transactions, insiders dumped 1,359,096 shares.
Vanguard Total Stock Market Index, Vanguard 500 Index Fund, and Washington Mutual Investors Fund are the top 3 mutual funds which are holding stakes in Pfizer Inc. Vanguard Total Stock Market Index is currently holding 157.91 million shares of worth totaling $6.08 billion. The company recently came selling -0.44 million shares which brought its stake up to 2.84% of the company’s outstanding shares. Vanguard 500 Index Fund sold -0.7 million shares, after which its hold over company’s outstanding shares shrunk to 2.06%, leaving 114.55 million shares with the mutual fund that have a worth of about $4.41 billion. Washington Mutual Investors Fund, after buying 75.96 million shares, have now control over 1.37% of the stake in the company. It holds 9.63 million shares of worth $2.92 billion.
Pfizer Inc. (NYSE: PFE) started trading at $37.96, below -$0.09 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $37.86, or with a loss of -0.50%. Stock saw a price change of -2.22% in past 5 days and over the past one month there was a price change of -3.57%. Year-to-date (YTD), PFE shares are showing a performance of -3.37% which increased to 7.92% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $27.88 but also hit the highest price of $40.97 during that period. While comparing its average daily trading volume of 30.91 million shares, we see that about 20.65 million changed hands on the day. The stock is currently trading -1.37% below its 20-day simple moving average (SMA20), while that difference is up 4.29% for SMA50 and it goes to 3.59% higher than SMA200.
SSgA Funds Management, Inc. acquired 298.9 million shares of Pfizer Inc. having value of about $11.5 billion. Data submitted at the U.S SEC by SSgA Funds Management, Inc. revealed that the firm now holds 6.28 million shares in the company valued at close to $237795971.94, or have control over 2.15% stake in the company. Pfizer Inc. (NYSE: PFE) currently have 5.55B outstanding shares and institutions hold larger chunk of about 71.90% of that. Holding of mutual funds in the company is about 32.02% while other institutional holders and individual stake holders have control over 39.89% and 0.29% of the stake respectively.
The stock has a current market capitalization of $209.52B and its 3Y-monthly beta is at 0.69. PE ratio of stock for trailing 12 months is 15.41, while it has posted earnings per share of $2.46 in the same period. Its PEG reads 2.87 and has Quick Ratio of 1.20 while making debt-to-equity ratio of 0.99. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PFE, volatility over the week remained 1.30% while standing at 1.46% over the month.
Analysts are in expectations that Pfizer Inc. (PFE) stock would likely to be making an EPS of $0.71 in the current quarter, while forecast for next quarter ESPS is $0.63 and it is $3.34 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.6 which is $0.79 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.75 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 62.30% while it is estimated to increase by 13.92% in next year. EPS is likely to shrink at an annualized rate of 5.37% for next 5-years, compared to annual growth of 14.70% made by the stock over the past 5-years.
Analysts at 16 brokerage firms have issued recommendations for the Pfizer Inc. (PFE)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.50. Out of those 16 Wall Street analysts, 6 recommended a “Buy” rating, while 8 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by SVB Leerink on June 16, 2020 offering a Mkt perform rating for the stock and assigned a target price of $40 to it. Coverage by Standpoint Research stated Pfizer Inc. (PFE) stock as a Buy in their note to investors on February 27, 2020, suggesting a price target of for the stock. On February 27, 2020, Barclays Initiated their recommendations, while on February 06, 2020, Mizuho Initiated their ratings for the stock with a price target of. Stock get an Outperform rating from RBC Capital Mkts on January 07, 2020.